Rein Therapeutics gets FDA Fast Track for LTI-03 in IPF
Rein Therapeutics (RNTX) says the U.S. FDA granted Fast Track Designation for LTI-03 in idiopathic pulmonary fibrosis.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.